AI Patent Eligibility: PTAB Rejection Explained
- The Patent Trial and Appeal Board (PTAB) recently rejected a patent submission for an artificial intelligence (AI) powered medical tool, raising concerns for AI-driven innovation.
- The PTAB acknowledged the application presented new information,facilitated by machine learning,linking biomarkers to lung cancer growth.
- The patent application covered a machine learning system predicting a human's disease state based on biomarkers.
The Patent Trial and Appeal Board (PTAB) just delivered a harsh reality check, rejecting a patent for an AI medical tool due to subject matter ineligibility. This pivotal decision, detailed in Ex parte Michalek, emphasizes the hurdles facing AI-driven innovation and highlights the complex intersection of patent law and machine learning. Addressing the primary_keyword of “AI patent eligibility” is now more critical than ever. The PTAB flagged the invention,despite its novelty in cancer applications,as a natural law,setting a stern precedent. Applicants must proactively address eligibility issues, focusing on how their AI enhances technological function. This ruling impacts the patent strategies for AI-enabled inventions across all industries. For comprehensive insights, News Directory 3 has the full story. Discover what’s next for securing AI patents in this evolving landscape.
Patent Board Rejects AI Medical Tool Patent Over Eligibility
The Patent Trial and Appeal Board (PTAB) recently rejected a patent submission for an artificial intelligence (AI) powered medical tool, raising concerns for AI-driven innovation. The decision in Ex parte Michalek hinged not on the tool’s novelty, but on whether it met subject matter eligibility requirements under U.S.patent law.
The PTAB acknowledged the application presented new information,facilitated by machine learning,linking biomarkers to lung cancer growth. The applicant had previously overcome objections regarding the invention’s novelty and non-obviousness. Though, the PTAB, citing U.S. Patent Office guidance, deemed the claims ineligible.
The patent application covered a machine learning system predicting a human’s disease state based on biomarkers. While the applicant successfully defended the invention’s novelty, the remaining hurdle was subject matter eligibility—whether the invention qualifies for patent protection.
U.S. patent law protects processes, machines, and compositions of matter, but excludes natural laws, mathematical concepts, and abstract ideas. Differentiating these categories, especially for AI, is complex. The Patent Office offers guidance on subject matter eligibility for AI-related inventions, including examples of eligible and ineligible innovations.
Despite acknowledging the invention’s novelty,the PTAB classified it as a natural law and mathematical concept. The board referenced a Patent Office example deeming a patient risk assessment tool ineligible because it improved an abstract idea, not computer function. The PTAB didn’t explore whether describing a treatment could have bolstered the application’s eligibility.
While the case involved medical technology, the issues impact patent strategies for AI-enabled inventions across industries. Patent applicants should anticipate similar scrutiny and address potentially strained interpretations of Patent Office guidance. Proactive application drafting, aligned with guidance and relevant examples, is crucial for smoother prosecution of AI patents.
What’s next
The Michalek decision underscores the importance of carefully crafting patent applications for AI-driven inventions to address subject matter eligibility concerns proactively. Applicants should focus on demonstrating how their AI improves technological function, rather than merely automating abstract ideas.